secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bio Green Med Solution, Inc. (BGMS)
CIK:        0001130166
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0001104659-24-036148
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclacel posts FY2023 net loss $22.6M; cash runway only into Q2 2024
--------------------------------------------------------------------

- Net loss $22.6M for FY2023 vs $21.2M in FY2022; R&D expenses $19.2M vs $20.3M.
- Cash and equivalents $3.4M at Dec 31, 2023; pro forma $6.3M incl $2.9M UK R&D tax credit received after year end.
- Company expects available cash to fund planned programs only into Q2 2024.
- On track to start oral fadraciclib Phase 2 proof-of-concept in 1H 2024; final Phase 1 data expected.
- Plogosertib to switch to new oral formulation; preclinical data support precision medicine in ARID1A/SMARCA-mutated cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130166/000110465924036148/0001104659-24-036148-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130166/000110465924036148/tm249239d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-036148

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer